

IMMUCELL CORP /DE/  
Form 8-K  
August 28, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

**Date of Report: August 28, 2012**  
**(Date of earliest event reported)**

**ImmuCell Corporation**  
**(Exact name of registrant as specified in its charter)**

**ME**  
**(State or other jurisdiction**  
**of incorporation) 001-12934**

**(Commission File Number) 01-0382980**  
**(IRS Employer**  
**Identification Number)**

**56 Evergreen Drive**  
**(Address of principal executive offices) 04103**  
**(Zip Code)**

**207-878-2770**  
**(Registrant's telephone number, including area code)**

**Not Applicable**  
**(Former Name or Former Address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 7.01. Regulation FD Disclosure**

**Item 9.01. Financial Statements and Exhibits**

**(a) Financial statements:**

None

**(b) Pro forma financial information:**

None

**(c) Shell company transactions:**

None

**(d) Exhibits**

99.1 Press Release of ImmuCell Corporation dated August 28, 2012

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 28, 2012

**IMMUCELL CORPORATION**

By: /s/ Michael F. Brigham

Michael F. Brigham  
*President and CEO*

---

**Exhibit Index** **Exhibit No.** **Description** 99.1 Press Release of ImmuCell Corporation dated August 28, 2012